Semaglutide 1 mg in Your Wegovy Journey: What This Step Actually Means

Picture where you are in the schedule

You started at 0.25 mg, a dose whose only job was to let your system settle in quietly. Four weeks later came 0.5 mg. Now, at week nine, your prescriber moves you to 1 mg semaglutide. It can feel like you are still on the lower end of the scale, and that is true. But the design is deliberate. Wegovy's titration exists because GLP-1 medicines work on the gut as well as the brain, and the nausea, queasiness and digestive disruption that sometimes come early are far less severe when the dose rises slowly. The 1 mg pen (like the others in the Wegovy sequence) delivers a single once-weekly subcutaneous injection, typically into the abdomen, thigh or upper arm.

One misconception worth setting aside gently: some people assume a slower climb through the steps means the treatment is not working. It does not. The schedule is the same for everyone starting out, regardless of how much weight a person wants to lose or how well they are tolerating the medicine so far. If anything, people who move through the early doses with fewer side effects are better placed to reach the maintenance dose and stay there.

If you want a clear picture of how the whole semaglutide dose ladder fits together, the Wegovy doses overview sets it out plainly.

What changes (and what you might actually notice) at this semaglutide dose

For many people, 1 mg is the first dose where appetite suppression feels more reliably present across the whole week rather than peaking in the day or two after the injection. That is partly because semaglutide's half-life means it accumulates over successive doses, and by the time 1 mg arrives, your baseline level of the medicine is higher than it was at 0.25 mg. Reduced hunger, a greater sense of fullness after smaller portions, and less interest in food between meals are the effects people most commonly report. Some find these effects subtle at 1 mg; others find them pronounced. Both are within the range of normal responses.

Side effects at this step tend to be gastrointestinal: nausea, constipation, loose stools, indigestion, or a general feeling of digestive sluggishness. For most people these ease within a couple of weeks. If they are persistent or severe (especially any intense, lasting abdominal pain that radiates to the back) that warrants prompt medical attention rather than waiting it out. The MHRA highlighted acute pancreatitis as a known (though uncommon) risk with GLP-1 medicines in a safety communication in early 2026, and sudden or severe stomach pain should always be taken seriously. You can report suspected side effects at the MHRA's Yellow Card scheme.

Practical detail worth knowing: each Wegovy pen at every strength is pre-set. There is no dial to adjust. You inject the dose that is in the pen your prescriber has authorised for this stage of your treatment.

Where 1 mg fits in the path toward the maintenance dose

After four weeks at 1 mg semaglutide, the schedule moves to 1.7 mg, which is followed by the step up to 3 mg semaglutide, and then to the 2.4 mg maintenance dose, the level at which the clinical trials showing meaningful weight reduction were conducted. The STEP 1 trial, published in the New England Journal of Medicine, reported an average reduction of around 15% of body weight over 68 weeks at 2.4 mg alongside lifestyle changes. That evidence is what underpins Wegovy's licence, and it is also the evidence behind NICE's recommendation of semaglutide for weight management.

The 1 mg semaglutide pen is a stage in that journey rather than a destination. It is also not the end of the upward titration for everyone: in 2026, the MHRA approved a higher maintenance dose for adults with obesity (BMI 30 or above), and you can read more about what reaching 5 mg of semaglutide involves as part of that extended titration. If you are curious about how that fits into the picture, there is more on what the higher semaglutide doses involve.

For anyone wondering whether the early doses (including 0.25 mg) do anything meaningful at all, there is a useful read on what the starter dose is actually doing.

Private access and what clinical oversight looks like at this stage

On the NHS, Wegovy is available through specialist weight management services, and waiting lists in many areas are lengthy. Private treatment through a regulated online pharmacy is an alternative for people who are clinically suitable but do not want to wait. If you are considering the private route, it is worth understanding what good oversight looks like at the 1 mg stage and beyond: a GPhC-registered prescriber should be reviewing your progress and any evidence of how you are tolerating the current dose before authorising the next pen. At nume, every repeat order, including any dose increase, goes through a fresh clinical review by a real prescriber. There is more on how that process works on the Wegovy treatment page.

You can also explore the broader picture of what is involved in starting treatment through our consultation service, or look at what medically supervised weight loss involves more generally. Our clinical team oversees every prescription at the pharmacy. If you have a question that has not been answered here, the FAQs cover a wide range of topics, and you can always reach our support team directly. When you are ready to talk through your options, speaking to our prescribers is the right next step, there is no obligation and no cost for the consultation itself.